learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
Search
forLearn
5 / 801 resultslearn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn Calcipotriene
learn Beclomethasone
learn 18β-glycyrrhetinic acid
Research
5 / 1000+ results
research Biologics in the management of childhood atopic dermatitis
Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
research Sycosis Barbae Treated With Bimekizumab
Bimekizumab effectively treated a man's chronic beard hair loss.
research 128 Bimekizumab led to rapid & deep normalisation of molecular signatures associated with PASI sub-components, preceding clinical skin clearance
research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis
Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
research 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
Community Join
5 / 1000+ resultscommunity EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Has anyone tried Winlevi (a.k.a. Clascoterone or CB-03-01) on their scalp yet?
The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.
community Pyrludimide (KX-826) or Breezula (clascoterone)
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.
community Beeezula off label (winlevi compounded)
User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.
community FDA approves Cassiopea's WINLEVI (CB-03-01, 1% formulation) for Acne
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.